### EVIDENCE REVIEW

**1847** Pancreatic adenocarcinoma: Beyond first line, where are we?  
Cherri S, Noventa S, Zaniboni A

### REVIEW

**1864** Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect  
Heda R, Yazawa M, Shi M, Bhaskaran M, Aloor FZ, Thuluvath PJ, Satapathy SK

**1883** Repurposing metformin for the treatment of gastrointestinal cancer  
Cunha Junior AD, Bragagnoli AC, Costa FO, Carvalheira JBC

**1905** Mesenchymal stromal cell secretome in liver failure: Perspectives on COVID-19 infection treatment  

### MINIREVIEWS

**1920** Artificial intelligence applications in inflammatory bowel disease: Emerging technologies and future directions  
Gubatan J, Levitte S, Patel A, Balabanis T, Wei MT, Sinha SR

**1936** Post-pancreatitis diabetes mellitus and excess intra-pancreatic fat deposition as harbingers of pancreatic cancer  
Petrov MS

**1943** BRCA mutated pancreatic cancer: A change is coming  
Rosen MN, Goodwin RA, Vickers MM

**1959** Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond  
Shengir M, Elgara M, Sebastiani G

### ORIGINAL ARTICLE

**Basic Study**

**1973** S100 calcium binding protein A6 and associated long noncoding ribonucleic acids as biomarkers in the diagnosis and staging of primary biliary cholangitis  
Dong XH, Dai D, Yang ZD, Yu XO, Li H, Kang H

**1993** Long non-coding RNA TP73-AS1 promotes pancreatic cancer growth and metastasis through miRNA-128-3p/GOLM1 axis  
Wang B, Sun X, Huang KJ, Zhou LS, Qiu ZJ
Retrospective Study

2015 Prediction of microvascular invasion in solitary hepatocellular carcinoma ≤ 5 cm based on computed tomography radiomics
Liu P, Tan XZ, Zhang T, Gu QB, Mao XH, Li YC, He YQ

2025 Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study
Yang DH, Wang WP, Zhang Q, Pan HY, Huang YC, Zhang JJ

Observational Study

2039 Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact
Detlie TE, Lindstrøm JC, Jahnsen ME, Finnes E, Zoller H, Moum B, Jahnsen J
ABOUT COVER
Editorial Board Member of World Journal of Gastroenterology, Abhinav Vasudevan, Bachelor of Medicine, MPH, PhD, FRACP, Advanced Inflammatory Bowel Disease Fellow, Mayo Clinic, 200 1st Street SW, Rochester, MN 55902, United States. vasudevan.abhinav@mayo.edu

AIMS AND SCOPE
The primary aim of World Journal of Gastroenterology (WJG, World J Gastroenterol) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING
The WJG is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2020 edition of Journal Citation Report® cites the 2019 impact factor (IF) for WJG as 3.665; IF without journal self cites: 3.534; 5-year IF: 4.048; Ranking: 35 among 88 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG’s CiteScore for 2019 is 7.1 and Scopus CiteScore rank 2019: Gastroenterology is 17/137.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Yu-Jie Ma; Production Department Director: Xiang Li; Editorial Office Director: Ze-Mao Gong.

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF
Andrzej S Tarnawski, Subrata Ghosh

EDITORIAL BOARD MEMBERS
http://www.wjgnet.com/1007-9327/editorialboard.htm

PUBLICATION DATE
May 7, 2021

COPYRIGHT
© 2021 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com

© 2021 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com
Retrospective Study

Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study

Dan-Hong Yang, Wei-Ping Wang, Qiang Zhang, Hong-Ying Pan, Yi-Cheng Huang, Jia-Jie Zhang

ORCID number: Dan-Hong Yang 0000-0002-1235-942X; Wei-Ping Wang 0000-0002-0304-9956; Qiang Zhang 0000-0002-0516-8588; Hong-Ying Pan 0000-0002-8433-3851; Yi-Cheng Huang 0000-0003-0058-9251; Jia-Jie Zhang 0000-0001-6095-0364.

Author contributions: Yang DH designed the research study; Yang DH and Wang WP analyzed the data and wrote the manuscript; Zhang Q, Pan HY, Huang YC and Zhang JJ collected the data; All authors have read and approved the final manuscript.

Supported by Zhejiang Provincial Natural Science Foundation, No. LY18H190002.

Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Zhejiang Provincial People’s Hospital (2020QT155, Hangzhou, Zhejiang Province, China).

Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.

Abstract

BACKGROUND
Antiviral therapy cannot completely block the progression of hepatitis B to hepatocellular carcinoma (HCC). Furthermore, there are few predictors of early HCC progression and limited strategies to prevent progression in patients with HBV-related cirrhosis who receive nucleos(t)ide analog (NA) therapy.

AIM
The study aim was to clarify risk factors and the diagnostic value of alpha-fetoprotein (AFP) for HCC progression in NA-treated hepatitis B virus (HBV)-related cirrhosis patients.

METHODS
In this retrospective cross-sectional study, we analyzed the clinical data of 266 patients with HBV-related cirrhosis who received NA treatment between February 2014 and April 2020 at Zhejiang Provincial People’s Hospital. The patients were divided into two groups, 145 who did not progress to HCC (No-HCC group), and 121 who progressed to HCC during NA treatment (HCC group). The logistic regression analysis was used to analyze the risk factors of HCC progression. The diagnostic value of AFP for HCC was evaluated by receiver operating characteristic (ROC) curve analysis.

RESULTS
Univariate analysis showed that age ≥ 60 years ($P = 0.001$), hepatitis B and alcoholic etiology ($P = 0.007$), smoking history ($P < 0.001$), family history of HBV-
INTRODUCTION

Liver cancer has the third-highest cancer mortality rate worldwide[1]. Hepatocellular carcinoma (HCC) is one of the most common subtypes of liver cancer and is the sixth most prevalent cancer type. In most countries, the HCC mortality rates have increased in recent decades[2]. HCC is the fourth most common malignant tumor type in China, accounting for over 55% of the total number of HCC cases[3]. Infection with the hepatitis B virus (HBV) greatly increases the incidence of HCC because HBV causes chronic hepatitis B (CHB), liver cirrhosis, and ultimately HCC[4,5]. The estimated risk of developing HCC was observed to be 25 to 37-fold higher in hepatitis B surface antigen (HBsAg) carriers compared with noninfected patients HBV infection is one of the most important contributors to the pathogenesis of HCC[6-8]. Over the past 30 years, antiviral drugs, especially nucleos(t)ide analogs (NAs), have been widely used in clinical practice and have substantial long-term effects on the inhibition of HBV replication, namely, delaying and reducing the occurrence and development of hepatitis B-related events. Many studies have shown that antiviral therapy can considerably decrease the incidence of HCC, even for patients in whom CHB has progressed to cirrhosis[9,10]. However, antiviral therapy does not completely block the progression of CHB to liver cancer[11,12]. In the current study, we analyzed the risk factors of HCC progression in patients with HBV-related cirrhosis who received...
NAs therapy for at least 6 mo. The diagnostic value of the serum alpha-fetoprotein (AFP) level was evaluated in those patients by receiver operating characteristic (ROC) curve analysis. The study results increase our understanding of HCC pathogenesis and help to provide HCC prevention and control strategies.

MATERIALS AND METHODS

Patients and design
This cross-sectional study retrospectively enrolled 266 patients with HBV-related cirrhosis who were treated with NA antiviral therapy at Zhejiang Provincial People’s Hospital between February 2014 and April 2020. The 266 patients were divided into two groups, 145with cirrhosis who did not progress to HCC during the observation period (No-HCC group), and 121 with cirrhosis who progressed to HCC (HCC group). The inclusion criteria were: (1) Age ≥ 18 years; (2) Treatment with lamivudine (LAM), adefovir (ADV), telbivudine, entecavir (ENT), or tenofovir (TDF) nucleoside or NAs for at least 6 mo; (3) Diagnosis of cirrhosis established by either histology (progressive fibrosis, nodule formation, and loss of hepatic architecture) or clinical data (symptoms and signs of cirrhosis, abnormal liver function, and ultrasonic identification). Demographic, clinical, laboratory, imaging, and pathology data were collected during the patient’s hospital stay. The severity of cirrhosis was classified by the Child-Pugh criteria. Patients with HBV-related cirrhosis were diagnosed in accord with the guidelines for the prevention and treatment of chronic hepatitis B formulated by the Hepatology Branch and the Infectious Diseases Branch of the Chinese Medical Association[13,14]; and (4) HCC and hepatitis diagnoses confirmed by clinical and serological characteristics, ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), hepatic arteriography with digital subtraction angiography (DSA) and pathological examination consistent with the hepatitis and primary liver cancer clinical diagnosis criteria[15,16]. The exclusion criteria were: (1) Hepatitis C virus, hepatitis D virus, or human immunodeficiency virus infection; (2) Autoimmune hepatitis and drug hepatitis; and (3) Hepatocarcinoma prior to antiviral treatment or within 6 mo after antiviral treatment. The study received no support from any pharmaceutical company and was approved by the Ethics Committee of the Zhejiang Provincial People’s Hospital (2020QT155), Hangzhou, Zhejiang Province, China.

Data collection and study design
The data collected from the electronic medical record system were age, sex, history of drinking and smoking, alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), glutamyltranspeptidase (GGT), alkaline phosphatase (ALP), total bilirubin, fasting blood glucose (FBG), AFP, prothrombin time (PT), presence of ascites, hepatic encephalopathy, Child-Pugh score and classification, and family history of HBV, hepatitis B, and HCC. Serological markers of hepatitis B, serum content of HBV DNA, and history of NA treatment were reported by the patients or their families. All patients in the cohort were followed-up for 3 years or until death. Serum liver function was tested by routine automated techniques using an Olympus AU5400 automated analyzer (Olympus, Tokyo, Japan). HBsAg, hepatitis B e-antigen (HBeAg), and hepatitis B e-antibody were assessed at baseline by chemiluminescence immunoassay (Abbott ARCHITECT i2000 SR analyzer; Abbott Diagnostics, Chicago, IL, United States). The serum HBV DNA load was assessed by RT-PCR using a LightCycler PCR system (Roche LightCycler480 II fluorescence quantitative PCR) in strict accordance with the instructions provided with the reagent kit (Shenzhen PG Biotech Co. Ltd, China). The detection limit was approximately 100 viral genome IU/mL. Genotypic resistance to LAM and ADV were determined at baseline by direct sequencing of the PCR amplification products. The serum AFP tumor marker was assayed by electrochemiluminescence. The study protocol conformed to the 1975 Declaration of Helsinki ethical guidelines for clinical studies.

Statistical analysis
Descriptive data were expressed as means ± SD or n (%). Continuous variables were compared using Student’s t-test. Skewness distribution data were reported as the median with the range and were analyzed using the Mann–Whitney U test. Categorical variables were analyzed using Fisher’s exact test or Pearson’s χ² test. A logistic regression model was used to analyze single factors, and multivariate analysis with stepwise regression was used to identify statistically significant variables in the
single-factor analysis. The diagnostic performance of the serum AFP level was evaluated using ROC curves. The cutoff value, which was the maximum area under the ROC curve (AUROC), and accuracy were calculated with 95% confidence intervals (CIs). A *P* value of less than 0.05 was determined to indicate statistical significance. The SPSS statistical package (version 22.0; SPSS, Chicago, IL, United States) was used for the statistical analysis.

**RESULTS**

**Clinical characteristics of HBV-related cirrhosis patients receiving NA therapy**

The clinical features of the No-HCC and the HCC group were compared. There were no significant differences between the two groups in the sex ratio, duration of NA therapy, HBsAg level, HBeAg positivity, jaundice index, Child-Pugh class B ratio, and PT level (*P* > 0.05). The HCC group included significantly more patients older than 60 years of age and patients with increased levels of ALT, AST, GGT, ALP, and FBG, and decreased levels of ALB than the No-HCC group. The HCC group also contained more patients with mixed etiology (alcohol + HBV), history of smoking, family history of HBV-related HCC, LAM resistance, Child-Pugh class C status, and an AFP > 20 μg/L and fewer HBV DNA-negative and Child-Pugh class A patients than the No-HCC group (Table 1).

**Risk factors for HCC progression in HBV-related cirrhosis patients receiving NA therapy**

We analyzed factors associated with HCC progression in HBV-related cirrhosis patients who received NA therapy. Univariate analysis found age ≥ 60 years (*P* = 0.002), HBV + alcohol mixed etiology (*P* = 0.007), smoking history (*P* < 0.001), family history of HBV-related HCC (*P* = 0.002), LAM resistance (*P* = 0.046), HBV DNA negativity (*P* = 0.023), AST > 80 U/L (*P* = 0.002), GGT > 120 U/L (*P* = 0.001), ALP > 250 U/L (*P* = 0.001), FBG ≥ 6.16 mmol/L (*P* = 0.001), and Child-Pugh class C (*P* = 0.005) to be significantly related to HCC (Table 2). Multivariate analysis showed that age ≥ 60 years [hazard ratio (HR) = 3.089, 95%CI: 1.437-6.631, *P* = 0.004], smoking history (HR = 4.001 95%CI: 1.836-8.716, *P* < 0.01), family history of HBV-related HCC (HR = 6.763, 95%CI: 1.253-36.499, *P* < 0.05), LAM resistance (HR = 2.949, 95%CI: 1.207-7.208, *P* = 0.018), HBV DNA negative (HR = 0.026, 95%CI: 0.007-0.139, *P* < 0.01), and FBG ≥ 6.16 mmol/L (HR = 7.219, 95%CI: 3.716-14.024, *P* < 0.01) independently predicted HCC progression in patients with HBV-related cirrhosis who received NAs therapy (Table 3).

**Serum AFP levels in the No-HCC and HCC groups**

In the HCC group, there were 56 patients with serum AFP levels > 20 μg/L, but that was seen in only 17 patients in the No-HCC group (*P* < 0.001). In the HCC group, 65 patients had AFP levels < 20 μg/L. The AFP levels of 37 patients in the HCC group were > 400 μg/L, but only two patients in the No-HCC group levels > 400 μg/L (*P* < 0.001, Table 4). The 17 patients in the No-HCC group with AFP levels > 20 μg/L were followed for 1 year. Their AFP level was determined every month and showed a dynamic decline, returning to normal within 1 year. All patients underwent enhanced MRI of imaging of the liver. We believe that hepatitis B activity, rather than HCC, led to the AFP abnormality. The AFP level distributions in the two groups are shown in Figures 1 and 2.

**Serum AFP has limited ability to diagnose HBV-related HCC**

We investigated the value of using serum AFP to diagnose HCC in patients who had HBV-related cirrhosis and were receiving NAs therapy. The AUROC of serum AFP for the diagnosis of HCC was 0.746 (95%CI: 0.674-0.818). The sensitivity of serum AFP in diagnosing HCC in those patients was 0.609, and the specificity was 0.818. The positive predictive value of HCC was 22.51%, the negative predictive value of HCC was 46.07%, the cutoff was 9.00, and the Youden index was 0.427 (Figure 3).

**DISCUSSION**

HBV infection remains a major risk factor for the development of cirrhosis and HCC[17]. Patients with chronic HBV are at risk of developing liver-related complica-
Table 1 Comparison of the clinical characteristics of patients with and without hepatocellular carcinoma

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>no-HCC group (n = 145)</th>
<th>HCC group (n = 121)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥ 60 yr, n (%)</td>
<td>41 (28.3)</td>
<td>64 (52.9)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>99 (68.3)</td>
<td>91 (75.2)</td>
<td>0.133</td>
</tr>
<tr>
<td>Etiology of liver cirrhosis, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HBV</td>
<td>101 (60.7)</td>
<td>76 (62.8)</td>
<td>0.563</td>
</tr>
<tr>
<td>HBV + alcohol</td>
<td>31 (21.4)</td>
<td>45 (37.2)</td>
<td>0.006</td>
</tr>
<tr>
<td>HBV + HEV</td>
<td>1 (0.6)</td>
<td>0 (0.0)</td>
<td>-</td>
</tr>
<tr>
<td>HBV + schistosome</td>
<td>1 (0.6)</td>
<td>0 (0.0)</td>
<td>-</td>
</tr>
<tr>
<td>Smoking history, n (%)</td>
<td>21 (14.5)</td>
<td>51 (42.1)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Family history of HBV-related HCC, n (%)</td>
<td>10 (6.9)</td>
<td>23 (19.0)</td>
<td>0.004</td>
</tr>
<tr>
<td>Medication history</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of NA treatment, yr, median (P25, P75)</td>
<td>3.9 (2.1, 5.8)</td>
<td>5.4 (2.3, 6.9)</td>
<td>0.067</td>
</tr>
<tr>
<td>LAM resistance, n (%)</td>
<td>18 (12.4)</td>
<td>27 (22.3)</td>
<td>0.021</td>
</tr>
<tr>
<td>HBsAg level, IU/L, median (P25, P75)</td>
<td>255.0 (56.0, 678.0)</td>
<td>269.0 (67.0, 656.0)</td>
<td>0.456</td>
</tr>
<tr>
<td>HBeAg positive, n (%)</td>
<td>37 (25.5)</td>
<td>21 (17.4)</td>
<td>0.136</td>
</tr>
<tr>
<td>HBV DNA negative, n (%)</td>
<td>67 (46.2)</td>
<td>39 (32.2)</td>
<td>0.033</td>
</tr>
<tr>
<td>ALB, U/L</td>
<td>36.29 ± 7.98</td>
<td>33.34 ± 6.62</td>
<td>0.002</td>
</tr>
<tr>
<td>ALT, U/L, median (P25, P75)</td>
<td>30.0 (18.00, 37.00)</td>
<td>33.00 (23.00, 47.00)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>AST, U/L, median (P25, P75)</td>
<td>33.00 (20.00, 46.00)</td>
<td>61.50 (32.75, 160.75)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>ALP, U/L, median (P25, P75)</td>
<td>99.00 (73.00, 126.00)</td>
<td>134.50 (92.00, 198.85)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>TB, μmol/L, median (P25, P75)</td>
<td>20.41 (13.81, 44.60)</td>
<td>24.46 (16.60, 42.80)</td>
<td>0.192</td>
</tr>
<tr>
<td>FBS, mmol/L, median (P25, P75)</td>
<td>5.17 ± 0.68</td>
<td>6.99 ± 1.31</td>
<td>0.025</td>
</tr>
<tr>
<td>Ascites, n (%)</td>
<td>33 (20.0)</td>
<td>43 (34.7)</td>
<td>0.022</td>
</tr>
<tr>
<td>Child-Pugh class, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>81 (55.9)</td>
<td>55 (45.5)</td>
<td>0.001</td>
</tr>
<tr>
<td>B</td>
<td>38 (26.2)</td>
<td>26 (21.5)</td>
<td>0.561</td>
</tr>
<tr>
<td>C</td>
<td>26 (17.9)</td>
<td>40 (33.1)</td>
<td>0.002</td>
</tr>
<tr>
<td>AFP ≥ 20 μg/L, n (%)</td>
<td>14 (9.7)</td>
<td>56 (46.3)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>PT s, median (P25, P75)</td>
<td>13.25 (11.80, 14.20)</td>
<td>13.51 (12.41, 15.02)</td>
<td>0.475</td>
</tr>
</tbody>
</table>

AFP: Alpha-fetoprotein; ALB: Albumin; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; FBS: Fasting blood sugar; GGT: Glutamyl transpeptidase; HBeAb: Hepatitis B e-antibody; HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; LAM: Lamivudine; PT: Prothrombin time; SD: Standard deviation; TB: Total bilirubin.

In this study, we investigated the clinical characteristics of HCC progression in patients with HBV-related cirrhosis who received antiviral therapy with NAs.

In China, 77% of cirrhosis cases and 84% of HCC cases are caused by HBV infection[18]. Antiviral therapy can reduce but not eliminate the risk of developing HCC[19-21]. The annual incidence of HCC ranges from 0.01% to 5.4% in patients with CHB who are treated with ENT or TDF[19,22]. NAs antiviral treatments can markedly inhibit viral replication and improve liver necrosis, inflammation, and fibrosis. However, NAs cannot eliminate covalently closed template DNA (cccDNA) produced during hepatitis B viral replication or clear the integrated HBV genome; therefore, NAs cannot completely block hepatitis B cirrhosis from developing into HCC[12,21]. The persistence of cccDNA and an integrated HBV genome is the basis for hepatitis B cirrhosis progressing to primary liver cancer[23,24].
<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No-HCC group (n = 145)</th>
<th>HCC group (n = 121)</th>
<th>Univariate adjusted HR (95%CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yr</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 60</td>
<td>40 (27.6)</td>
<td>65 (52.9)</td>
<td>2.664 (1.606-4.418)</td>
<td>0.001</td>
</tr>
<tr>
<td>&lt; 60</td>
<td>105 (72.4)</td>
<td>56 (46.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HBV + alcohol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>31 (21.4)</td>
<td>45 (37.2)</td>
<td>2.384 (1.271-4.473)</td>
<td>0.007</td>
</tr>
<tr>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking history</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>21 (14.5)</td>
<td>51 (42.1)</td>
<td>4.073 (2.281-7.273)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Family history of HBV-related HCC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>10 (6.9)</td>
<td>23 (19.0)</td>
<td>3.546 (1.573-7.998)</td>
<td>0.002</td>
</tr>
<tr>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LAM resistance</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>18 (12.4)</td>
<td>27 (22.3)</td>
<td>2.284 (1.214-4.297)</td>
<td>0.011</td>
</tr>
<tr>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HBV DNA negative</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>67 (46.2)</td>
<td>39 (32.2)</td>
<td>0.559 (0.339-0.922)</td>
<td>0.023</td>
</tr>
<tr>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALB (g/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 35</td>
<td>67 (46.2)</td>
<td>62 (51.2)</td>
<td>1.223 (0.754-1.984)</td>
<td>0.414</td>
</tr>
<tr>
<td>≥ 35</td>
<td>78 (53.8)</td>
<td>59 (48.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50-100</td>
<td>13 (9.0)</td>
<td>15 (12.4)</td>
<td>1.324 (0.612-2.866)</td>
<td>0.476</td>
</tr>
<tr>
<td>&gt; 100</td>
<td>10 (7.0)</td>
<td>14 (11.6)</td>
<td>1.138 (0.482-2.688)</td>
<td>0.768</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40-80</td>
<td>32 (22.1)</td>
<td>24 (19.8)</td>
<td>0.919 (0.713-0.514)</td>
<td>0.783</td>
</tr>
<tr>
<td>&gt; 80</td>
<td>16 (10.3)</td>
<td>31 (29.8)</td>
<td>2.899 (0.436-1.767)</td>
<td>0.002</td>
</tr>
<tr>
<td>GGT (U/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>60-120</td>
<td>15 (10.3)</td>
<td>20 (16.5)</td>
<td>1.853 (0.892-3.847)</td>
<td>0.098</td>
</tr>
<tr>
<td>&gt; 120</td>
<td>8 (5.1)</td>
<td>28 (23.1)</td>
<td>5.663 (1.075-2.573)</td>
<td>0.001</td>
</tr>
<tr>
<td>ALP (U/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>125-250</td>
<td>36 (24.8)</td>
<td>45 (38.8)</td>
<td>1.609 (0.862-1.028)</td>
<td>0.073</td>
</tr>
<tr>
<td>&gt; 250</td>
<td>6 (4.1)</td>
<td>21 (17.4)</td>
<td>4.865 (0.667-2.993)</td>
<td>0.001</td>
</tr>
<tr>
<td>FBG (mmol/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 6.16</td>
<td>19 (13.1)</td>
<td>37 (30.6)</td>
<td>3.3179 (0.587-1.902)</td>
<td>0.001</td>
</tr>
<tr>
<td>&lt; 6.16</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ascites class</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>33 (22.8)</td>
<td>43 (35.5)</td>
<td>0.834 (0.412-0.060)</td>
<td>0.142</td>
</tr>
<tr>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 3 Multivariate analysis of factors associated with hepatitis B-related cirrhosis progression to hepatocellular carcinoma in nucleos(t)ide analog-treated patients

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>β</th>
<th>SE</th>
<th>Wald</th>
<th>( P ) value</th>
<th>OR (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥ 60 yr</td>
<td>1.127</td>
<td>0.390</td>
<td>8.347</td>
<td>0.004</td>
<td>3.089 (1.437-6.631)</td>
</tr>
<tr>
<td>Smoking history</td>
<td>1.387</td>
<td>0.397</td>
<td>12.180</td>
<td>&lt; 0.01</td>
<td>4.001 (1.836-8.716)</td>
</tr>
<tr>
<td>Family history of HBV-related HCC</td>
<td>1.911</td>
<td>0.860</td>
<td>4.938</td>
<td>&lt; 0.05</td>
<td>6.763 (1.253-36.499)</td>
</tr>
<tr>
<td>LAM resistance</td>
<td>1.082</td>
<td>0.456</td>
<td>5.638</td>
<td>0.018</td>
<td>2.949 (1.207-7.208)</td>
</tr>
<tr>
<td>HBV DNA negative</td>
<td>-3.479</td>
<td>0.816</td>
<td>19.427</td>
<td>&lt; 0.01</td>
<td>0.026 (0.007-0.139)</td>
</tr>
<tr>
<td>FBG ≥ 6.16 mmol/L</td>
<td>1.977</td>
<td>0.339</td>
<td>34.030</td>
<td>&lt; 0.01</td>
<td>7.219 (3.716-14.024)</td>
</tr>
</tbody>
</table>

CI: Confidence interval; FBG: Fasting blood glucose; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; LAM: Lamivudine OR: Odds ratio; SE: Standard error.

Table 4 Comparison of the alpha-fetoprotein level distributions in patients with and without hepatocellular carcinoma, \( n \) (%)

<table>
<thead>
<tr>
<th>AFP (μg/L)</th>
<th>No-HCC group (( n = 145 ))</th>
<th>HCC group (( n = 121 ))</th>
<th>( P ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 20</td>
<td>128 (88.27)</td>
<td>65 (53.72)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>20-100</td>
<td>12 (8.27)</td>
<td>14 (11.57)</td>
<td>0.51</td>
</tr>
<tr>
<td>100-200</td>
<td>1 (0.69)</td>
<td>2 (1.77)</td>
<td>0.231</td>
</tr>
<tr>
<td>200-400</td>
<td>2 (1.38)</td>
<td>3 (2.48)</td>
<td>1</td>
</tr>
<tr>
<td>≥ 400</td>
<td>2 (1.38)</td>
<td>37 (30.58)</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma.
hepatitis. The combination of a family history of liver cancer and hepatitis B serum markers is associated with a greater than 70-fold increase in HCC risk[30]. Super-additive and super-multiplicative interactions may exist between a family history of liver cancer and HBV infection that increase the risk of the development of liver cancer[31]. Our study found that a family history of HBV-related HCC is a risk factor of progression in cirrhotic patients receiving antiviral therapy (95%CI: 1.253-36.499, \( P < 0.05 \)). Our results suggest that patients with HBV-related cirrhosis who smoke should quit smoking and cultivate a healthy lifestyle to reduce the risk of developing HCC[32,33]. Furthermore, close monitoring should be carried out if a patient’s first-degree relative develops HBV-related HCC during antiviral treatment.

LAM has been used as an antiviral treatment for hepatitis B for the past 20 years in China. Some Chinese patients with hepatitis B-related cirrhosis have previously undergone primary LAM monotherapy. Studies have shown that long-term LAM antiviral therapy can delay disease progression, reduce liver function decompensation, and reduce the incidence of HCC[34,35]. The inflammation seen in liver histology can improve in patients with hepatitis B-related cirrhosis when they are treated with LAM, but with a prolonged treatment time, the incidence of drug-resistant viral mutation increases[34,36]. The clinical benefit of LAM is limited by the emergence of resistant mutant strains and viral breakthrough. Although some LAM-resistant CHB patients have received ADV combination therapy or sequential ENT or TDF monotherapy, some of these patients did not experience a beneficial treatment effect and still had continuous replication of HBV in the liver[37,38]. In patients with LAM resistance, those with cirrhosis had a higher HCC risk than non-cirrhotic patients. Rescue treatment with ADV in patients who developed viral breakthrough did not appear to reduce the risk of HCC compared with untreated patients without remission[11]. In
Figure 3 Receiver operating characteristic curve analysis of alpha-fetoprotein to diagnose hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis receiving nucleos(t)ide analog therapy. ROC: Receiver operating characteristic.

our study of patients treated with antiviral therapy for more than 6 mo, the number of HBV DNA-negative patients in the HCC group was lower than that in the No-HCC group. Many studies have found a correlation between serum HBV DNA levels and the occurrence of HCC in patients with hepatitis B. Kaneko et al[39] reported that detectable HBV DNA was significantly associated with a higher risk of HCC development compared with continuously undetectable HBV DNA. Chen et al[40] found that the incidence of HCC increased with serum HBV DNA level at study entry in a dose-response relationship ranging from 108/100,000 person-years for an HBV DNA level of < 300 copies/mL to 1152/100,000 person-years for an HBV DNA level of 1 million copies/mL or more. The corresponding cumulative incidence rates of HCC were 1.3% and 14.9%.

Even if the serum HBV DNA level in patients with hepatitis B-related cirrhosis is kept at a low level (< 2000 IU/mL), the risk of HCC is still high[41]. As shown in our study, HBV DNA negativity (HR = 0.026, 95%CI: 0.007-0.139, P < 0.01) independently predicted HCC progression in patients with HBV-related cirrhosis who received NAs therapy. Thus, to help avoid HCC progression, hepatitis B patients should continue to maintain an HBV DNA-negative status. Therefore, drugs with a high genetic barrier to resistance are suggested as first-line antiviral drugs for HBV therapy, and are recommended by current guidelines. Drugs such as ETV, TDF, and TDF alafenamide fumarate should be selected to generate a sustained antiviral treatment response and to reduce the occurrence of HBV resistance and the incidence of HCC[42,43].

As an important metabolic organ, the liver plays a key role in maintaining glucose homeostasis. Studies have found a positive relationship between liver cancer and diabetes mellitus[44,45]. Cell and animal experiments have shown that type 2 diabetes and male sex are associated with HCC development. Gao et al[46] demonstrated that heterozygous deletion of the Ncoa5 gene caused spontaneous development of HCC exclusively in male mice, and NCOA5 deficiency increased susceptibility to both glucose intolerance and HCC. In a prospective cohort study, adjusted multivariable analysis showed that participants with 4.82 mmol/L ≤ FBG ≤ 5.49 mmol/L had a 47% increased risk of HCC, and those with an FBG > 5.49 mmol/L had a 69% increased risk[47]. In our study, the FBG level in the HCC group was higher than that in the No-HCC group (Table 1), and FBG ≥ 6.16 mmol/L was an independent risk factor for the HCC progression in patients with hepatitis B-related cirrhosis receiving NA antiviral treatment. Controlling blood sugar concentrations might be a way to decrease the risk of HCC in the Chinese population.

AFP is a glycoprotein that exists in a variety of different glycotypes. AFP has been used in the screening, diagnosis, efficacy evaluation, and prognosis evaluation of HCC. AFP elevation is commonly seen in active hepatitis, pregnancy, liver cancer, and embryonic tumors[48,49]. Previous studies reported that there was a significant correlation between serum AFP levels and the tumor size in liver cancer, and that the sensitivity and specificity of AFP depended on the selected serum level threshold[20,50]. Liu et al[51] found that approximately one-third of patients with
HCC had normal serum AFP levels and that the level was related to the volume of liver cancer lesions, vascular invasion, and differentiation. In our study, we found 56 patients with a serum AFP > 20 µg/L, and 19 with serum AFP levels between 20 and 400 µg/L and with HCC confirmed by imaging and histopathological examination of liver masses. However, an AFP level of < 20 µg/L did not exclude the possibility of HCC. This study showed that 65 patients with a serum AFP of < 20 µg/L had space-occupying lesions that were confirmed as HCC by MRI enhancement, histopathology, and liver DSA examination. That indicates that more sensitive diagnostic markers of HCC must be developed. In addition, more sensitive serum tumor markers such as milk fat globule-EGF factor 8, osteopontin, miRNA classifier, glypican-3[52-54], and others should be actively investigated or combined to identify HCC at an early stage[55]. However, their clinical sensitivity and specificity must first be confirmed.

This study had some limitations. First, it was not prospective. The impact of antiviral treatment time and the amount of smoking and drinking on the development of HCC require confirmation in prospective studies with larger sample sizes. Second, longer follow-up and surveillance of HBV-related cirrhosis patients receiving NA therapy is necessary to observe whether they progress to HCC in their lifetime, even though the 145 cirrhotic patients with NA therapy did not progress to HCC during the observation period. Third, additional molecular markers should be assessed for their ability to provide an early diagnosis of HCC in patients with HBV-related cirrhosis. Some data indicate that the currently used potent NAs can reduce but not eliminate the risk of HCC. The inability to eliminate HCC risk might persist because of risk factors that are not amenable to change by antiviral therapy or because of events that may have taken place before treatment initiation.

**CONCLUSION**

In conclusion, age ≥ 60 years, a history of smoking, family history of HBV-related HCC, LAM resistance, HBV DNA negativity, and FBG ≥ 6.16 mmol/L were risk factors for HCC progression in patients with HBV-related cirrhosis who received NAs therapy. Patients with HBV-related cirrhosis should be treated with NA antiviral therapy that has a high genetic barrier to resistance[7] in order to improve the long-term response to antiviral therapy, to maintain an HBV DNA-negative status, and to prevent subsequent hepatitis activity. The early identification of HCC in patients with HBV-related cirrhosis remains difficult. Patients who receive antiviral therapy with NAs, especially those older than 60 years of age, should avoid smoking, control their blood sugar at a reasonable level, and undergo routine imaging examination of liver biochemistry and serum AFP evaluation. If space-occupying lesions are identified, the patient should undergo liver CT or MRI enhancement, or even liver DSA examination to identify HCC as promptly as possible, even if the AFP level is within the normal range.

**ARTICLE HIGHLIGHTS**

**Research background**

Antiviral therapy cannot completely block the progression of hepatitis B to hepatocellular carcinoma (HCC). Furthermore, there are few early predictors of HCC progression and early identification is difficult in patients with HBV-related cirrhosis who receive nucleos(t)ide analog (NA) therapy. The study is helpful to provide HCC prevention and control strategies by analyzing the risk factors of HCC progression and the diagnostic value of AFP for HCC in those people.

**Research motivation**

The study objective was to identify factors that affect the occurrence of HCC and how to identify early HCC in patients with hepatitis B virus (HBV)-related cirrhosis who receive NA therapy. The results can improve the understanding of the development of HCC in those patients so as to improve the early detection and prevention of HCC.

**Research objectives**

The study objectives were to clarify risk factors and the diagnostic value of alpha-fetoprotein (AFP) for HCC progression in patients with HBV-related cirrhosis treated with NAs and to provide new strategies for prevention and control of HCC in those
patients.

Research methods
Logistic regression analysis was used to analyze the risk factors of HCC progression. The diagnostic value of AFP for HCC was evaluated by receiver operating characteristic curve analysis.

Research results
The study showed that age ≥ 60 years, smoking history, family history of HCC, lamivudine resistance, HBV DNA negativity, fasting blood sugar ≥ 6.16 mmol/L were independent risk factors of HCC progression. Serum AFP had limited diagnostic value for HCC. The results provide a meaningful strategy for early prediction and identification for HCC in those patients.

Research conclusions
A retrospective cross-sectional study was conducted to analyze risk factors of HCC progression in HBV-related cirrhosis patients receiving NA therapy. Metabolic effects of fasting blood sugar levels on the progress of HCC were seen during the receipt of NA therapy. The diagnostic value of the serum AFP level was evaluated in those patients.

Research perspectives
The study results will change the strategies used to prevent HCC in patients with HBV-related cirrhosis an receive NA therapy.

REFERENCES


Zhonghua Shiyuan He linchunag Gannanbang Zazhi 2015; 9: 570-589 [DOI: 10.3877/cma.j.issn.1673-1358.2015.05.001]

Yang DH et al. HCC progression in HBV-related cirrhosis

10.1177/1073274817729245


Yang DH et al. HCC progression in HBV-related cirrhosis

Oncol 2015; 16: 804-815 [PMID: 26088272 DOI: 10.1016/S1470-2045(15)00048-0]
